Patient Perspective-Where Does the Value for Money of a Treatment Really Lie? [PDF]
Mathieson TA +3 more
europepmc +1 more source
Advancing Evidence Generation in Small, Diverse, Understudied Population. [PDF]
Mitra A +5 more
europepmc +1 more source
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets. [PDF]
Ziółkowska EA +5 more
europepmc +1 more source
Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2. [PDF]
Priglinger CS +9 more
europepmc +1 more source
First case of use of cerliponase alfa in a child with neuronal ceroid lipofuscinosis type 2 in Bahia
Érica Otoni Pereira Miranda +8 more
openaire +1 more source
Psychiatric manifestations in Neuronal ceroid lipofuscinoses. [PDF]
Della Vecchia S +5 more
europepmc +1 more source
PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy. [PDF]
Chandra S, Pahan K.
europepmc +1 more source
Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom. [PDF]
Mole SE +14 more
europepmc +1 more source
Risk management plans and drug safety in Canada: A cross-sectional study. [PDF]
Lexchin J.
europepmc +1 more source
Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience. [PDF]
Radić Nišević J +4 more
europepmc +1 more source

